These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 27029036)

  • 21. Clinical molecular testing for ASXL1 c.1934dupG p.Gly646fs mutation in hematologic neoplasms in the NGS era.
    Montes-Moreno S; Routbort MJ; Lohman EJ; Barkoh BA; Kanagal-Shamanna R; Bueso-Ramos CE; Singh RR; Medeiros LJ; Luthra R; Patel KP
    PLoS One; 2018; 13(9):e0204218. PubMed ID: 30222780
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Making sense of the myelodysplastic/myeloproliferative neoplasms overlap syndromes.
    Tiu RV; Sekeres MA
    Curr Opin Hematol; 2014 Mar; 21(2):131-40. PubMed ID: 24378705
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical, biological, and prognostic implications of SF3B1 co-occurrence mutations in very low/low- and intermediate-risk MDS patients.
    Janusz K; Izquierdo MM; Cadenas FL; Ramos F; Sánchez JMH; Lumbreras E; Robledo C; Del Real JS; Caballero JC; Collado R; Bernal T; Pedro C; Insunza A; de Paz R; Xicoy B; Salido E; García JS; Mínguez SS; García CM; Muñoz AMS; Barba MS; Rivas JMH; Abáigar M; Campelo MD
    Ann Hematol; 2021 Aug; 100(8):1995-2004. PubMed ID: 33409621
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A two-step approach for sequencing spliceosome-related genes as a complementary diagnostic assay in MDS patients with ringed sideroblasts.
    Janusz K; Del Rey M; Abáigar M; Collado R; Ivars D; Hernández-Sánchez M; Valiente A; Robledo C; Benito R; Díez-Campelo M; Ramos F; Kohlmann A; Cañizo CD; Hernández-Rivas JM
    Leuk Res; 2017 May; 56():82-87. PubMed ID: 28222336
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differential U2AF1 mutation sites, burden and co-mutation genes can predict prognosis in patients with myelodysplastic syndrome.
    Wang H; Guo Y; Dong Z; Li T; Xie X; Wan D; Jiang Z; Yu J; Guo R
    Sci Rep; 2020 Oct; 10(1):18622. PubMed ID: 33122737
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chromothripsis Is a Recurrent Genomic Abnormality in High-Risk Myelodysplastic Syndromes.
    Abáigar M; Robledo C; Benito R; Ramos F; Díez-Campelo M; Hermosín L; Sánchez-Del-Real J; Alonso JM; Cuello R; Megido M; Rodríguez JN; Martín-Núñez G; Aguilar C; Vargas M; Martín AA; García JL; Kohlmann A; Del Cañizo MC; Hernández-Rivas JM
    PLoS One; 2016; 11(10):e0164370. PubMed ID: 27741277
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumor suppressor microRNAs are downregulated in myelodysplastic syndrome with spliceosome mutations.
    Aslan D; Garde C; Nygaard MK; Helbo AS; Dimopoulos K; Hansen JW; Severinsen MT; Treppendahl MB; Sjø LD; Grønbæk K; Kristensen LS
    Oncotarget; 2016 Mar; 7(9):9951-63. PubMed ID: 26848861
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ASXL1 mutation as a surrogate marker in acute myeloid leukemia with myelodysplasia-related changes and normal karyotype.
    Prats-Martín C; Burillo-Sanz S; Morales-Camacho RM; Pérez-López O; Suito M; Vargas MT; Caballero-Velázquez T; Carrillo-Cruz E; González J; Bernal R; Pérez-Simón JA
    Cancer Med; 2020 Jun; 9(11):3637-3646. PubMed ID: 32216059
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The diagnostic utility of targeted gene panel sequencing in discriminating etiologies of cytopenia.
    Zheng G; Chen P; Pallavajjalla A; Haley L; Gondek L; Dezern A; Ling H; De Marchi F; Lin MT; Gocke C
    Am J Hematol; 2019 Oct; 94(10):1141-1148. PubMed ID: 31350794
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Clonal haematopoiesis: A concise review].
    Danlos FX; Papo M; Micol JB
    Rev Med Interne; 2019 Oct; 40(10):684-692. PubMed ID: 31126662
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular Testing in Patients with Suspected Myelodysplastic Syndromes.
    Moyo TK; Savona MR
    Curr Hematol Malig Rep; 2016 Dec; 11(6):441-448. PubMed ID: 27734261
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Analytical validation and performance characteristics of a 48-gene next-generation sequencing panel for detecting potentially actionable genomic alterations in myeloid neoplasms.
    Rosenthal SH; Gerasimova A; Ma C; Li HR; Grupe A; Chong H; Acab A; Smolgovsky A; Owen R; Elzinga C; Chen R; Sugganth D; Freitas T; Graham J; Champion K; Bhattacharya A; Racke F; Lacbawan F
    PLoS One; 2021; 16(4):e0243683. PubMed ID: 33909614
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The high frequency of the U2AF1 S34Y mutation and its association with isolated trisomy 8 in myelodysplastic syndrome in Asians, but not in Caucasians.
    Kim SY; Kim K; Hwang B; Im K; Park SN; Kim JA; Hwang SM; Bang D; Lee DS
    Leuk Res; 2017 Oct; 61():96-103. PubMed ID: 28938223
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value.
    Smith AE; Mohamedali AM; Kulasekararaj A; Lim Z; Gäken J; Lea NC; Przychodzen B; Mian SA; Nasser EE; Shooter C; Westwood NB; Strupp C; Gattermann N; Maciejewski JP; Germing U; Mufti GJ
    Blood; 2010 Nov; 116(19):3923-32. PubMed ID: 20693430
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pedigree investigation, clinical characteristics, and prognosis analysis of haematological disease patients with germline TET2 mutation.
    Wu X; Deng J; Zhang N; Liu X; Zheng X; Yan T; Ye W; Gong Y
    BMC Cancer; 2022 Mar; 22(1):262. PubMed ID: 35279121
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mutations and karyotype predict treatment response in myelodysplastic syndromes.
    Idossa D; Lasho TL; Finke CM; Ketterling RP; Patnaik MM; Pardanani A; Gangat N; Tefferi A
    Am J Hematol; 2018 Nov; 93(11):1420-1426. PubMed ID: 30152885
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular landscape and clonal architecture of adult myelodysplastic/myeloproliferative neoplasms.
    Palomo L; Meggendorfer M; Hutter S; Twardziok S; Ademà V; Fuhrmann I; Fuster-Tormo F; Xicoy B; Zamora L; Acha P; Kerr CM; Kern W; Maciejewski JP; Solé F; Haferlach C; Haferlach T
    Blood; 2020 Oct; 136(16):1851-1862. PubMed ID: 32573691
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The prognostic impact of mutations in spliceosomal genes for myelodysplastic syndrome patients without ring sideroblasts.
    Kang MG; Kim HR; Seo BY; Lee JH; Choi SY; Kim SH; Shin JH; Suh SP; Ahn JS; Shin MG
    BMC Cancer; 2015 Jun; 15():484. PubMed ID: 26115659
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Progression, transformation, and unusual manifestations of myelodysplastic syndromes and myelodysplastic-myeloproliferative neoplasms: lessons learned from the XIV European Bone Marrow Working Group Course 2019.
    Hebeda K; Boudova L; Beham-Schmid C; Orazi A; Kvasnicka HM; Gianelli U; Tzankov A
    Ann Hematol; 2021 Jan; 100(1):117-133. PubMed ID: 33128619
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular similarity between myelodysplastic form of chronic myelomonocytic leukemia and refractory anemia with ring sideroblasts.
    Gelsi-Boyer V; Cervera N; Bertucci F; Brecqueville M; Finetti P; Murati A; Arnoulet C; Mozziconacci MJ; Mills KI; Cross NC; Vey N; Birnbaum D
    Haematologica; 2013 Apr; 98(4):576-83. PubMed ID: 23065512
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.